Whole Body / General174 citations
The present study established a 2605 MHz RF-EMR (SAR=1
Bioeffects Seen
Yu G, Zhu Y, Song C, Chen L, Tang Z, Wu T · 2023
Insufficient information to determine key finding.
Plain English Summary
Summary written for general audiences
Insufficient information provided. The study record contains only a partial title indicating a 2605 MHz RF-EMR exposure study with a SAR (Specific Absorption Rate) of 1, but no abstract or complete methodology details were provided to accurately summarize the study's aims or findings.
Why This Matters
The partial title suggests this is an RF-EMF exposure study, likely examining biological or technical effects at 2605 MHz frequency. A complete abstract would be needed to assess the study's design, organism/system tested, and actual results.
Exposure Information
Specific exposure levels were not quantified in this study.
Cite This Study
Yu G, Zhu Y, Song C, Chen L, Tang Z, Wu T (2023). The present study established a 2605 MHz RF-EMR (SAR=1.
Show BibTeX
@article{yu_g_zhu_y_song_c_chen_l_tang_z_wu_t_ce3919,
author = {Yu G and Zhu Y and Song C and Chen L and Tang Z and Wu T},
title = {The present study established a 2605 MHz RF-EMR (SAR=1},
year = {2023},
doi = {10.1016/s0140-6736(22)02600-9},
}Quick Questions About This Study
This appears to be a database categorization error. The study compared stroke medications tenecteplase and alteplase in 1,430 patients, with no electromagnetic field exposures or EMF-related measurements involved in the research design or outcomes.
No, these are both thrombolytic medications used to dissolve blood clots in stroke patients. Neither drug has any connection to electromagnetic fields, wireless radiation, or other EMF sources that would warrant inclusion in EMF health research.
The trial enrolled 1,430 acute ischemic stroke patients across 53 Chinese medical centers to compare the effectiveness and safety of two clot-dissolving drugs, finding tenecteplase was non-inferior to the standard alteplase treatment.
This particular study examined only pharmaceutical interventions without any electromagnetic field components. However, separate EMF research has investigated whether certain electromagnetic exposures might affect stroke recovery, though that's unrelated to this medication comparison trial.
Misclassified studies can dilute research quality and mislead those seeking EMF health information. Proper categorization is essential for maintaining the integrity of EMF research databases and ensuring accurate evidence synthesis for public health guidance.